^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR exon 19 deletion + TMB-L |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M- cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy
Excerpt:
A 66-year-old man complained with chest tightness, hemoptysis, and back pain. CT scans revealed a mass in the right lung and metastases to the bilateral lungs, liver, adrenal gland, mediastinal lymph nodes, and bone. He was also diagnosed with EGFR 19del-positive LUAD and treated with icotinib followed by osimertinib. He also acquired EGFR T790M-cis-C797S. The patient had low TMB also and benefited from a PD-1 inhibitor camrelizumab combined with platinum-based doublet chemotherapy as late-line treatment with a progression-free survival (PFS) of 8 months.
DOI:
10.21037/atm-22-2436
